Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Jun 1, 2015 → Jun 1, 2016
NCT ID
NCT02492165About Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02492165. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02492165 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis